Medpace’s 20% Crash: Why the Earnings Beat Couldn’t Save the Stock
Ticker: MEDP | Event: Q1 2026 earnings release, April 22, 2026 | Stock reaction: ~20% drop TL;DR Medpace posted Q1 2026 revenue of $706.6 million, up 26.5% year-over-year, yet the stock dropped roughly 20% after hours because forward indicators collapsed. The net book-to-bill ratio fell to 0.88, the weakest reading in more than a year […]
Five Things Worth Knowing About Medpace’s Record 2025
Summary Medpace (MEDP) posted $2.53 billion in full-year 2025 revenue, up 20% over 2024, driven heavily by metabolic trial volume ( Medpace Q4 Press Release). Q4 cancellations hit their highest absolute and percentage levels in over a year, dragging the net book-to-bill ratio to 1.04x versus an expected 1.15x ( Q4 Earnings Call Transcript). The […]
